Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD-1 Study
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Galcanezumab (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Acronyms REBUILD-1
- Sponsors Eli Lilly and Company
- 25 May 2023 This trial has been completed in Germany, according to European Clinical Trials database record.
- 27 Mar 2023 Planned End Date changed from 9 Jan 2024 to 30 Nov 2026.
- 27 Mar 2023 Planned primary completion date changed from 30 Dec 2022 to 30 Nov 2025.